PIN Pharma
A pioneering biopharmaceutical firm dedicated to creating broad-based immuno-modulatory therapies by synergizing the innate and adaptive immune systems.
A pioneering biopharmaceutical firm dedicated to creating broad-based immuno-modulatory therapies by synergizing the innate and adaptive immune systems.
PIN Pharma is a pioneering biopharmaceutical firm dedicated to creating broad-based immuno-modulatory therapies by synergizing the innate and adaptive immune systems. Established in 2011, the company is a venture-backed research and development entity specialized in immunotherapies, with a primary focus on oncology. However, its technology holds promise for applications in various other disease areas. The latest significant funding for PIN Pharma was a $6.75M Series A investment in January 2014, led by NGN Capital. The firm's innovative method for linking the innate and adaptive immune systems is at the core of its dedication to developing ground-breaking therapies with broader applications throughout the field of biotechnology and pharmaceuticals.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $6.75M | 1 |
|
01 Jan 2014 |
No recent news or press coverage available for PIN Pharma.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
